1. Give the Product Manufacturing, Stability, COA(Certificate of Analysis) Reports. 2. Storage, Transportation and Retailors Conditions report. 3. Get the third part study conducted on Quality from the samples a) lot from the product complaint was done. b)random market sample and c) control sample. All these reports must be shared. If there is fault in the product, the total batch should be recalled and the sorry in public domain should be asked and a BIG Thank you should be send to the Person who has brought this information into notice. An appropriate compensation needs to be given if there is any hard done, based on the damage and existing law.

When this type of concern arises within the pharmaceutical field, the first step is always to have at hand all the possible technical information and information from patients, authorities, clinical studies, pharmacovigilance reports, feedback from opinion leaders, etc. The second step is to analyze this data in a multidisciplinary way, always keeping in mind patient safety. The third step is to contact the regulatory authority, when the case so warrants, to alert about this situation. The fourth step is to rely on communication experts to manage messages to the specialized and general public.

Assure them with complete Data about the products... Assure them of safety measures how this product is safe. Assure clients regarding about pros and cons of the products.. Detailed with full transperancy about product and every detailed information. Explain the laws which protect the client interest.

Whenever this question arises from HCPs, -Share data product information as per the brochure and do not make false promises - If there is any journals, or study some one has done, with credible information share with the HCPs -If required connect them with product R&D department for more details.

Any creditable pharmaceutical company will always have clinical data from trials concerning any of their licensed formats available to share However, in my experience when I was part of a very creditable team to launch simvastatin OTC we were questioned all the time about its efficacy and contra indications and so pharmacists would not stock it despite being prescribed for years. Yet when an unlicensed vapes were brought to the market they were very happy to sell them without any proven data or licensing by the MHRA. Any HCA can always check the EMC for info concerning. If it is not registered than that says everything, and the customer should be wary of using the product.